IRL757
Apathy in Neurological Disorders (incl. PD)
Phase IActive
Key Facts
Indication
Apathy in Neurological Disorders (incl. PD)
Phase
Phase I
Status
Active
Company
About IRLAB Therapeutics
IRLAB Therapeutics is dedicated to transforming the lives of patients with Parkinson's disease through its innovative, data-driven discovery platform and focused clinical pipeline. The company's proprietary Integrative Screening Process (ISP) accelerates and de-risks drug discovery, having generated multiple clinical-stage candidates. With a Phase III-ready asset for dyskinesia and a strategic focus on the high-growth Parkinson's market, IRLAB is positioned to address significant unmet medical needs and create substantial value.
View full company profile